Table 4.
Antithrombotic and antiplatelet treatment
| Index diverticular bleeding (2007) | Most frequent indication | At the end of follow-up | Most frequent indication | |
|---|---|---|---|---|
| Anticoagulant or antiplatelet drugs, n (%) | 244 (66.8%) | Coronary vascular disease, 66 (27.9%) | 217 (59.4%) | Coronary vascular disease, 61 (28.1%) |
| Antiplatelet drugs, n (%) | 160 (43.8%) | Coronary vascular disease, 66 (41.3%) | 141 (38.6%) | Coronary vascular disease, 61 (43.3%) |
| Aspirin, n (%) | 135 (37.0%) | Coronary vascular disease, 55 (40.7%) | 115 (31.5%) | Coronary vascular disease, 47 (40.9%) |
| Clopidogrel, n (%) | 50 (13.7%) | Coronary vascular disease, 26 (52%) | 40 (11.0%) | Coronary vascular disease, 24 (60%) |
| Anti-vitamin K, n (%) | 102 (27.9%) | Cardiac arrhythmia, 52 (51%) | 91 (24.9%) | Cardiac arrhythmia, 44 (48.3%) |
| Bitherapya, n (%) | 41 (11.2%) | Coronary vascular disease, 16 (39%) | 28 (7.7 %) | Coronary vascular disease, 10 (38.5%) |
| Heparin, n | 1 | 3 | ||
| No treatment, n (%) | 121 (33.2%) | 148 (40.5%) | ||
| No information, n (%) | 0 | 10 (2.7%) |
a
Bitherapy: two-fold anticoagulation or antiplatelet treatment.
n: number of patients